PBLA
Market cap | $0.00 |
---|---|
Enterprise Value | - |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $0.0 |
Beta | 0.0 |
Outstanding Shares | 4,854,861 |
Avg 30 Day Volume | 0 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 0.0 |
---|---|
PEG | - |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | - |
Enterprise Value to EBIT | - |
Enterprise Value to Net Income | - |
Total Debt to Enterprise | - |
Debt to Equity | - |
No data
No data
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company's initial product candidate, SBP-101, is for the treatment of patients ...